The Russian Federation Ministry of Health has registered the drug “Solirekt, rectal solution 90 mg/ml + 9 mg/ml + 625 mg/ml" in microclysters 5 ml No. 4, No. 12. Manufacturer - FSUE Moscow Endocrine Plant
Marketing Authorization No. LР-008450.
The medicine belongs to the laxative pharmacotherapeutic group.
The indication for use of “Solirekt, rectal solution 90 mg/ml + 9 mg/ml + 625 mg/ml” is constipation, including with encopresis, as well as preparation for endoscopic (rectoscopy) and X-ray examination of the gastrointestinal tract.
The medicine is OTC.
The Enterprise plans to release the first commercial batches of the medicine in October 2022.
Comment type is not specified in the component properties.